for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quest Diagnostics Inc

DGX.N

現在値

147.20USD

変化

1.49(+1.02%)

出来高

73,337

本日のレンジ

146.66

 - 

147.78

52週レンジ

113.44

 - 

160.56

∙ 約20分前の相場を表示しています。

適時開示

Quest Diagnostics Says A Unit Of Co Experienced A Data Security Incident

Oct 8 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS INC - IN AUGUST 2021, REPROSOURCE, A UNIT OF CO EXPERIENCED A DATA SECURITY INCIDENT - FILING.QUEST DIAGNOSTICS - IN AUGUST SECURITY INCIDENT UNAUTHORIZED PARTY MAY HAVE ACCESSED OR ACQUIRED PROTECTED HEALTH INFORMATION OF REPROSOURCE PATIENTS.QUEST DIAGNOSTICS - IN AUGUST INCIDENT, UNAUTHORIZED PARTY MAY HAVE ACCESSED OR ACQUIRED PERSONALLY IDENTIFIABLE INFORMATION OF REPROSOURCE PATIENTS.QUEST DIAGNOSTICS - QUEST DIAGNOSTICS’ SYSTEMS WERE NOT IMPACTED BY REPROSOURCE SECURITY INCIDENT.QUEST DIAGNOSTICS - IN CONNECTION WITH INCIDENT, REPROSOURCE DISCOVERED PRESENCE OF RANSOMWARE, QUICKLY CONTAINED RANSOMWARE, AND RESTORED OPERATIONS.QUEST DIAGNOSTICS - BASED ON ANALYSIS TO DATE, REPROSOURCE ESTIMATES THAT DATA ACCESSED MAY CONTAIN PERSONAL INFORMATION OF ABOUT 350,000 PATIENTS.QUEST DIAGNOSTICS - QUEST DIAGNOSTICS DOES NOT BELIEVE THIS INCIDENT WILL HAVE A MATERIAL IMPACT ON ITS BUSINESS.Further company coverage: DGX.N. ((Reuters.Briefs@thomsonreuters.com;)).

Quest Diagnostics Updates Outlook For Full Year 2021

Sept 9 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS UPDATES OUTLOOK FOR FULL YEAR 2021.QUEST DIAGNOSTICS INC - REVENUES FOR FULL YEAR 2021 NOW EXPECTED TO BE $9.84-$10.09 BILLION COMPARED TO PREVIOUS OUTLOOK OF $9.54-$9.79 BILLION.QUEST DIAGNOSTICS - REPORTED DILUTED EPS FOR FULL YEAR 2021 NOW EXPECTED TO BE $12.54-$13.24 COMPARED TO PREVIOUS OUTLOOK OF $11.48-$12.18.QUEST DIAGNOSTICS - ADJUSTED DILUTED EPS FOR FULL YEAR 2021 NOW EXPECTED TO BE $11.65-$12.35 COMPARED TO PREVIOUS OUTLOOK OF $10.65-$11.35.QUEST DIAGNOSTICS - CASH PROVIDED BY OPERATIONS FOR FULL YEAR 2021 NOW EXPECTED TO BE AT LEAST $2 BILLION VERSUS PREVIOUS OUTLOOK OF AT LEAST $1.9 BILLION.QUEST DIAGNOSTICS - COVID-19 MOLECULAR TESTING VOLUMES WERE STRONGER THAN ANTICIPATED THROUGH END OF AUGUST.QUEST DIAGNOSTICS - LOW END OF CO'S OUTLOOK NOW ASSUMES AVERAGE COVID-19 VOLUMES OF AT LEAST 40,000 MOLECULAR TESTS PER DAY FOR H2 OF YEAR.

Quest Diagnostics Acquires Boca Raton-Based Nationwide Laboratory Services

Aug 24 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS ACQUIRES BOCA RATON-BASED NATIONWIDE LABORATORY SERVICES.QUEST DIAGNOSTICS - HAS ACQUIRED SELECT ASSETS OF NATIONWIDE LABORATORY SERVICES.QUEST DIAGNOSTICS - TESTING SERVICES PROVIDED BY NLS WILL TRANSITION TO QUEST'S FULL-SERVICE LABORATORY IN MIRAMAR, FL.QUEST DIAGNOSTICS - WILL ALSO ACQUIRE SELECT PATIENT SERVICE SITES IN SOUTH FLORIDA.

Quest Diagnostics Exec Says Rise in COVID-19 Testing To Some Extent Due To Delta Variant: Conf Call

July 22 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS EXECUTIVE SAYS IN RECENT WEEKS, HAVE SEEN COVID-19 PCR TESTING VOLUMES STABILIZE AND INCREASE MODESTLY: CONF CALL.QUEST DIAGNOSTICS EXECUTIVE SAYS INCREASE IN COVID-19 TESTING IS TO SOME EXTENT DUE TO EMERGENCE OF DELTA VARIANT: CONF CALL.QUEST DIAGNOSTICS EXECUTIVE SAYS LOWER END OF FY OUTLOOK ASSUMES AT LEAST 20,000 COVID-19 MOLECULAR TESTS PER DAY IN SECOND HALF OF 2021: CONF CALL.

Quest Diagnostics Sees FY2021 Reported Diluted EPS $11.48 To $12.18

July 22 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS; ESTABLISHES FULL YEAR 2021 OUTLOOK.ESTABLISHES FULL YEAR 2021 OUTLOOK.Q2 REPORTED DILUTED EPS OF $4.96.QTRLY ADJUSTED DILUTED EPS OF $3.18.Q2 REVENUES OF $2.55 BILLION, UP 39.5% FROM 2020.SEES 2021 CAPITAL EXPENDITURES APPROXIMATELY $400 MILLION.SEES FY 2021 NET REVENUES $9.54 BILLION TO $9.79 BILLION.SEES 2021 ADJUSTED DILUTED EPS $10.65 - $11.35.Q2 EARNINGS PER SHARE VIEW $2.87, REVENUE VIEW $2.38 BILLION -- REFINITIV IBES DATA.FY2021 EARNINGS PER SHARE VIEW $11.14, REVENUE VIEW $9.49 BILLION -- REFINITIV IBES DATA.SEES FY 2021 REPORTED DILUTED EPS $11.48 TO $12.18.

Quest Diagnostics Reports Q1 2021 Financial Results, Announces Plan For $1.5 Billion Accelerated Share Repurchase

April 22 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS; ANNOUNCES PLAN FOR $1.5 BILLION ACCELERATED SHARE REPURCHASE.Q1 REVENUES OF $2.72 BILLION, UP 49.3% FROM 2020.Q1 REPORTED DILUTED EARNINGS PER SHARE ("EPS") OF $3.46.QTRLY ADJUSTED DILUTED EPS OF $3.76, UP 298.9% FROM 2020.EXPECTS TO LAUNCH AN ACCELERATED SHARE REPURCHASE OF APPROXIMATELY $1.5 BILLION IN COMING DAYS.UPDATES OUTLOOK FOR FIRST HALF OF 2021.SEES H1 2021 NET REVENUE $5 BILLION TO $5.2 BILLION.SEES H1 ADJUSTED DILUTED EPS OF $6.30-$6.80.Q1 EARNINGS PER SHARE VIEW $3.71, REVENUE VIEW $2.64 BILLION -- REFINITIV IBES DATA.SEES H1 2021 EPS $7.51 TO $8.01.

Quest Diagnostics - CEO Stephen Rusckowski's FY 2020 Total Compensation Was $14.1 Mln

April 9 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS SAYS CEO STEPHEN RUSCKOWSKI 'S TOTAL COMPENSATION FOR FY2020 WAS $14.1 MILLION VERSUS $10.1 MILLION IN FY2019 - SEC FILING.QUEST DIAGNOSTICS SAYS FOR 2020, MEDIAN IDENTIFIED EMPLOYEE TO CEO PAY RATIO WAS ESTIMATED TO BE ABOUT 1 TO 197.

Iqvia Acquires Remaining Interest In Q2 Solutions From Quest Diagnostics

April 1 (Reuters) - Iqvia Holdings Inc <IQV.N>::IQVIA ACQUIRES REMAINING INTEREST IN Q2 SOLUTIONS FROM QUEST DIAGNOSTICS; RAISES FULL YEAR 2021 ADJUSTED DILUTED EPS GUIDANCE.ANNOUNCED ACQUISITION OF 40 PERCENT MINORITY SHARE OF Q(2) SOLUTIONS FROM QUEST DIAGNOSTICS FOR $760 MILLION.TRANSACTION HAS BEEN FINANCED THROUGH CASH ON HAND.TRANSACTION IS NOT EXPECTED TO IMPACT IQVIA'S TARGET NET LEVERAGE RATIO.TRANSACTION IS EXPECTED TO BE APPROXIMATELY $0.12 ACCRETIVE TO IQVIA'S 2021 ADJUSTED DILUTED EPS.TRANSACTION IS EXPECTED TO BE AT LEAST $0.18 ACCRETIVE TO 2022 ADJUSTED DILUTED EPS.SEES 2021 ADJUSTED DILUTED EPS $7.89 - $8.20.FY2021 EARNINGS PER SHARE VIEW $7.98 -- REFINITIV IBES DATA.

Zora Biosciences Licenses Ceramide Technology To Quest Diagnostics For Cardiovascular Mortality Prediction Test

March 15 (Reuters) - Quest Diagnostics Inc <DGX.N>::ZORA BIOSCIENCES LICENSES CERAMIDE TECHNOLOGY TO QUEST DIAGNOSTICS FOR CARDIOVASCULAR MORTALITY PREDICTION TEST.QUEST - EXPECTS TO BEGIN TO OFFER NEW TEST SERVICE IN U.S. THROUGH ITS CARDIOMETABOLIC CENTER OF EXCELLENCE AT CLEVELAND HEARTLAB AS SOON AS NEXT YEAR.QUEST -PLANS TO DEVELOP TEST SERVICE BASED ON ZORA'S CERAMIDE TECH AS AN AID IN IDENTIFYING PATIENTS AT RISK FOR CARDIOVASCULAR-RELATED DISEASE, DEATH.

Quest Diagnostics Says COVID-19 Testing Revenues Are Expected To Step Down In 2022

March 11 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS - COVID-19 TESTING REVENUES ARE EXPECTED TO STEP DOWN MEANINGFULLY IN 2022 - FILING.QUEST DIAGNOSTICS - BASE BUSINESS REVENUES (WHICH EXCLUDES COVID-19 TESTING) ARE EXPECTED TO FULLY RECOVER BY END OF 2021.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up